Revance Therapeutics, Inc. (NASDAQ:RVNC) is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 1.03 per share.
For the full year, analysts predict revenues of $ 8.19 million, while looking forward to loss of $ 4.31 per share.
Previous Quarter Performance
Revance Therapeutics, Inc. posted loss for the second quarter of $ 1.12 per share, from the revenue of $ 0.30 million. The quarterly revenues fell 57.75 percent compared with the same quarter last year. Street analysts expected Revance Therapeutics, Inc. to report loss of $ 1.01 per share on revenue of $ 0.41 million for the second quarter. The bottom line results missed street analysts by $ 0.11 or 10.89 percent, at the same time, top line results fell short of analysts by $ 0.11 million or 26.83 percent.
Stock Performance
On Friday, shares of Revance Therapeutics, Inc. has traded high as $ 27.46 and has cracked $ 26.30 on the downward trend, reaching $ 26.54 with volume of 300.10 thousand shares.
According to the previous trading day, closing price of $ 26.54, representing a 126.32 % increase from the 52 week low of $ 11.78 and a 22.99 % decrease over the 52 week high of $ 34.62.
The company has a market capital of $ 1.75 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, maintained by Needham & Company LLC at Buy rating, with $ 42.00 target price.
Conference Call
Revance Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.revance.com
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The companys lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX.
